NCT04016636View on ClinicalTrials.gov

A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

August 12, 2019

Primary Completion Date

August 30, 2021

Study Completion Date

October 15, 2022

Conditions
CLL
Interventions
OTHER

Standard of Care

Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 12 months.

Trial Locations (1)

1114

Fundaleu, Buenos Aires

All Listed Sponsors
collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

Mela Osorio Maria Jose

OTHER

NCT04016636 - A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter